Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas

NCT01942629 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT01942629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01942629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas
Lead sponsor
Rambam Health Care Campus
Phase
Observational
Overall status
Unknown status
Start date
October 31, 2013
Completion date
December 31, 2015
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, lung adenocarcinoma, pancreatic ductal adenocarcinoma